source
- J&J's IBD combo therapy misses statistical goal but will be tested in a focused patient subgroupJohnson & Johnson reported that its experimental combination of Tremfya and Simponi, called JNJ-4804, did not achieve a statistically significant improvement in a Phase 2b study of inflammatory bow…
- Expert outlines how to manage common skin and GI side effects of daraxonrasib in pancreatic cancerDr Pant, MD, a professor at MD Anderson Cancer Center, discussed the safety profile of daraxonrasib, a RAS(ON) multi-selective inhibitor being studied in pancreatic ductal adenocarcinoma. The drug…